CrystalGenomics

We strive to be a global biopharma leader whose mission is

to develop innovative, life-changing medicine

Pipeline

Ivaltinostat
  • Indication
    Treatment of lung inflammation and fibrosis caused by COVID-19
  • Development stage
    Preparing for a phase 2 clinical trial in the U.S. for moderate and severe COVID-19 patients

Ivaltinostat

Development of COVID-19 treatment plans
  • Acute Respiratory Distress Syndrome (ARDS) Is the leading cause of death for COVID-19 patients
  • ARDS induces acute pulmonary inflammation and fibrosis due to the disruption of immune homeostatis by continuously inducing an overactive state of the immune system
  • Anti-inflammatory and anti-fibrotic drugs are being developed worldwide for the treatment of COVID-19.
Ivaltinostat's competitive advantage
  1. 01

    Efficacy has been verified in various animal models, including ARDS models

  2. 02

    Limited safety concerns based on results from a Phase 1 clinical study in healthy adults

  3. 03

    Completed development of oral formulation of ivaltinostat for ease of use

Ivaltinostat's mechanism of action
  • Inhibition of key mechanisms of inflammatory cytokine production (reduction of angiotensinogen expression)
  • Anti-inflammatory function in acute lung injury mouse model (reduction of inflammatory cytokines IL-6, IL-1β, TNF-α expression)
  • Anti-inflammatory function in flu virus infection mouse model (reduction of inflammatory cytokines TNF-α and IFN-γ expression)
  • Suppression of immune hypersensitivity reaction through regulation of neutrophil count
  • Inhibition of the expression of fibrotic proteins (Collagen-1, Vimentin, Fibronectin)
References
  1. 1.

    Yoon, G.E. et al. Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production. Schmiedebergs Arch. Pharmacol. 393, 491-500 (2020).

  2. 2.

    Kim, Y.S. et al. The anti-fibrotic effects of CG-745, an HDAC inhibitor, in bleomycin and PHMG-induced mouse models. Molecules 24, 2792 (2019).